Recruiting studies: Esophageal Squamous Cell Carcinoma Stage Iii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizuma
Phase 2/Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07554456 PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
Phase N/A · 1 location(s) · Fudan University · NCT07697859 Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT07177794 A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC
Phase 3 · 1 location(s) · National Cancer Center, Japan · NCT04328948 Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2 · 1 location(s) · Akeso · NCT07263919 Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Phase 3 · 1 location(s) · Henan Cancer Hospital · NCT04280822 QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07463573 Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectabl
Phase 2 · 1 location(s) · Tongji University · NCT06304350 A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esopha
Phase 3 · 81 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07487896 Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
NA · 3 location(s) · Fudan University · NCT04519905 TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Phase 3 · 1 location(s) · Fudan University · NCT06676449 Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Phase 3 · 1 location(s) · Fudan University · NCT06190782 PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05357846 A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Phase 3 · 1 location(s) · Beijing Konruns Pharmaceutical Co., Ltd. · NCT06194734 Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
Phase 2/Phase 3 · 1 location(s) · Shanghai Zhongshan Hospital · NCT04973306 Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Phase 3 · 96 location(s) · NRG Oncology · NCT03801876 CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Phase 3 · 1 location(s) · Fudan University · NCT06964568 Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
Phase 3 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT04807673 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285 The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulat
Phase 3 · 1 location(s) · All India Institute of Medical Sciences · NCT05187091

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.